Articles

FDA officials approved pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma efficacy of this treatment was evaluated in KEYNOTE-868/NRG-GY018.

Quick Quiz: Prostate Cancer Edition

Prostate Cancer

Quick Quizzes

According to the National Cancer Institute, prostate cancer is the most common cancer in US men and the second highest cause of cancer death in this patient population. In fact, an estimated 299,010 new cases will be diagnosed in 2024 and approximately 12.9% of men will receive this diagnosis in their lifetime. Thus, a significant portion of your patients and their loved ones will be affected by the disease. As the nation spotlights men’s health awareness this June, test your knowledge on this prevalent disease.

Addressing Cancer Health Disparities: The No One Left Alone Initiative

By Rohan Nathwani; Arva Patel; Warner Kornberg; Asutosh Gor, MD; Sashi Naidu, MD; Viral Rabara, MD; Niyati Nathwani, MD; Kashyap Patel, MD

Health Disparities

Web Exclusives

Despite ranking among the top 6 wealthiest economies in the world per capita, the United States still has sizable health disparities among its citizens, which are rooted in social, economic, and environmental factors. Place of birth is more strongly associated with life expectancy than race or genetics.

Navigating the Complex Landscape of Oral Cancer Medication

Oral Oncolytics

Web Exclusives

Recognizing the complexities of treatment with oral medications is an important step toward successful outcomes.

Real-World Uptake and Utilization Patterns of Biosimilars in Clinical Practice

In this supplement, expert faculty offer detailed perspectives based on their experience to summarize, examine, and analyze the emerging results from studies of anticancer biosimilars and provide recommendations to improve the adoption of and access to biosimilar products.

Fruzaqla FDA Approved for Relapsed Metastatic Colorectal Cancer

FDA Approvals, News & Updates

December 2023, Vol 14, No 6

On November 8, 2023, the FDA approved fruquintinib (Fruzaqla; Takeda Pharmaceuticals), an inhibitor of VEGFR-1, -2, and -3, for the treatment of metastatic colorectal cancer (mCRC) in adults who received previous fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. The FDA granted fruquintinib priority review for this indication.

Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC

By William King

ESMO, Lung Cancer

December 2023, Vol 14, No 6

Madrid, Spain—A perioperative regimen of neoadjuvant nivolumab (Opdivo) plus chemotherapy followed by surgery and adjuvant nivolumab demonstrated a statistically significant and clinically meaningful improvement in event-free survival versus neoadjuvant chemotherapy plus placebo followed by surgery and adjuvant placebo in patients with resectable non–small cell lung cancer.

AVBCC Keynote: The Path to Innovation in Oncology

By Phoebe Starr

December 2023, Vol 14, No 6

At the 13th Annual Association for Value Based Cancer Care Summit, held October 18-20, 2023, in New York City, Scott Gottlieb, MD, Former Commissioner of the FDA, gave the keynote lecture on how to foster innovation in oncology.

FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Metastatic or Recurrent Nasopharyngeal Carcinoma

FDA Approvals, News & Updates

December 2023, Vol 14, No 6

On October 27, 2023, the FDA approved toripalimab-tpzi (Loqtorzi; Coherus BioSciences), a PD-1 monoclonal antibody, in combination with cisplatin and gemcitabine chemotherapy, for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma, and as a single agent for adults with recurrent, unresectable, or metastatic nasopharyngeal carcinoma that progressed during or after treatment with a platinum-containing chemotherapy.

Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of GEJ Adenocarcinoma

FDA Approvals, News & Updates

December 2023, Vol 14, No 6

On November 16, 2023, the FDA approved the use of pembrolizumab (Keytruda; Merck) with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Articles

Top Trending Articles

Stay In The Know

Articles

Page 7 of 330

Top Trending Articles

Stay In The Know